既往口服抗凝药使用情况对Asundexian与Apixaban疗效的影响:OCEANIC-AF预设亚组分析
两组出血率在使用Asundexian时均较低。
要点
- 房颤初治患者使用Asundexian的卒中/栓塞风险增加幅度小于经治患者。
- Asundexian出血率在初治和经治患者中均低于Apixaban。
核心结论
- 在OCEANIC-AF试验中,既往OAC初治的房颤患者使用Asundexian相比Apixaban的卒中或系统性栓塞增加幅度小于经治患者,且出血率相似较低。
主要发现
- Asundexian组初治患者卒中或系统性栓塞率为0.8%(10/1238),经治患者为1.4%(88/6177)。
- Apixaban组初治患者卒中或系统性栓塞率为0.6%(7/1255),经治患者为0.3%(19/6140)。
- Asundexian组初治患者大出血率为0.2%(2/1228),经治患者为0.2%(15/6145);Apixaban组初治为1.0%(13/1249),经治为0.7%(40/6115)。
临床怎么用
- 对于既往OAC初治的房颤患者,Asundexian相比Apixaban的卒中风险增加幅度较小,但需进一步研究确认。
- Asundexian在初治和经治患者中均显示较低出血率,但疗效差异需结合个体化评估。
局限性
- 机制未知,需进一步研究。
- 为预设探索性亚组分析,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with atrial fibrillation (AF), oral anticoagulants (OACs) reduce the risk of stroke. OBJECTIVE: To investigate if patients with less prior OAC exposure respond differently to a new OAC than patients with more OAC exposure. DESIGN, SETTING, AND PARTICIPANTS: In this prespecified exploratory subgroup analysis of the Oral Factor 11a Inhibitor Asundexian as Novel Antithrombotic-Atrial Fibrillation (OCEANIC-AF) randomized clinical trial, patients enrolled in the OCEANIC-AF trial were categorized as OAC naive or OAC experienced based on whether they had 6 or fewer weeks or more than 6 weeks of prior OAC use. The effect of asundexian vs apixaban was then compared on outcomes among patients who were OAC naive and OAC experienced. The study setting included 1035 sites in 38 countries, and participants were those enrolled in the OCEANIC-AF trial. Data were analyzed from June to July 2024. INTERVENTIONS: Asundexian, a novel factor XIa inhibitor, was compared with apixaban in patients with AF. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was stroke or systemic embolism. The main safety outcome was major bleeding. RESULTS: Of patients in the OCEANIC-AF trial, 2493 (17%) were OAC naive (mean [SD] age, 72.6 [8.6] years; 1464 male [59%]) and 12 317 (83%) were OAC experienced (mean [SD] age, 74.2 [7.5] years; 8132 male [66%]). In the asundexian arm, patients who were OAC naive had a stroke or systemic embolism rate of 0.8% (10 of 1238) compared with 1.4% (88 of 6177) in those who were OAC experienced. In the apixaban arm, patients who were OAC naive had a stroke or systemic embolism rate of 0.6% (7 of 1255) compared with 0.3% (19 of 6140) in those who were OAC experienced. Thus, patients who were OAC naive had a smaller increase in stroke or systemic embolism with asundexian compared with apixaban (hazard ratio [HR], 1.42; 95% CI, 0.54-3.73) than patients who were OAC experienced (HR, 4.66; 95% CI, 2.84-7.65; P for interaction =.03). Bleeding rates were lower among both OAC-naive patients (0.2% [2 of 1228]) and OAC-experienced patients (0.2% [15 of 6145]) assigned asundexian than among OAC-naive patients (1.0% [13 of 1249]) and OAC-experienced patients (0.7% [40 of 6115]) assigned apixaban. CONCLUSIONS AND RELEVANCE: In the OCEANIC-AF randomized clinical trial, patients with AF who were OAC naive had a smaller increase in stroke or systemic embolism and a similar lower rate of bleeding with asundexian compared with apixaban than patients who were OAC experienced. The mechanism of these findings is unknown and deserves further research. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05643573.
引用
- Alexander, Lydon, Piccini, et al. Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40136309. doi:10.1001/jamacardio.2025.0277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。